Your
Clinical Research
Development Concierge

Delivering high-quality, accelerated, and cost controlled clinical trial services through a partnership model.

The Celero Way

A pathway to high-quality, cost-controlled, accelerated trials tailored to your needs.

Celero’s accelerated controlled pathway and timelines
Celero Regulatory Services to meet global regulations

High Quality

Celero Regulatory Services, to prevent registration delays or failure

Cost Controlled

Celero Market Access, increasing or defining sales performance

Accelerated

Celero Regulatory Services to meet global regulations

Tailored

Celero Regulatory Services, to prevent registration delays or failure

Partnership Model

Celero Market Access, increasing or defining sales performance

Commercially Driven

Our Process: Q&A

At Celero, we prioritize rigorous adherence to established Standard Operating Procedures (SOPs) to guarantee top-tier quality in our clinical trials. Our dedicated teams are continually trained on both trial protocols and Good Clinical Practice (GCP), ensuring a consistent level of expertise across the board.


We emphasize regular site monitoring to validate data accuracy and uphold patient safety, supplemented by periodic independent audits that ensure consistent compliance and protocol adherence. Our adoption of validated electronic data capture systems is a testament to our commitment to unparalleled data integrity.


Our proactive risk management strategies, coupled with our transparent communication lines with stakeholders, mean that potential challenges are addressed promptly and efficiently. By placing unwavering emphasis on participant safety, maintaining meticulous records, strictly adhering to regulatory guidelines, and integrating constructive feedback mechanisms, we strive to consistently raise the bar for the quality and integrity of clinical trials.

Our startup & recruitment timelines are significantly shorter due to:  

  • Relationship and Experience with Regulators: We understand their expectations for submission contents. 
  • Strategic Country Selection: We opt for countries with commercial opportunities and unmet needs. This not only provides accelerated startup phases but also faster recruitment due to large populations in emerging markets and high prevalence of specific diseases,  in addition to accelerated registration in some cases. 
  • Recruitment Efficiency: Our access to large populations in emerging markets, combined with our global reach for multi-centric trials and collaboration with experienced Principal Investigators (PIs) in specific disease areas, expedites our recruitment process. 

Additionally, we have access to patient databases through our sites and PIs, ensuring a smoother recruitment phase. 

A cost-controlled agreement is our promise to efficiently manage the costs associated with your clinical trial, keeping them within the agreed budget. This offers a fixed clinical trial budget that is both predictable and controlled. This allows you to trust our services, knowing that unexpected costs and change orders are unlikely. At Celero we demonstrate financial responsibility, fostering a transparent and trusting relationship with our sponsors. 

We understand that every biotech company has unique needs. Our approach is tailored to your requirements, ensuring that every phase of the clinical trial, from startup to recruitment and final reporting, aligns with your specific objectives, outcomes, budget, and timelines. 

We do not only perform a scientific experiment (Clinical trial); At Celero we strategically select countries with high commercial and growth opportunities by addressing their unmet  needs. These strategies allow our sponsors to achieve accelerated registrations and high market share providing you with an optimal return on your clinical trial investment. 

Our partnership model signifies a collaborative approach. We don't see ourselves as just another vendor; we act as an extension of your clinical, registration and commercial team. This symbiotic relationship ensures that your objectives become our milestones, driving both parties towards shared success. 

Our Enablers

We provide an end-to-end commercially driven solution with global access to top industry experts, influential key opinion leaders (KOLs), regulatory authorities, premier clinical trial sites, and diverse patient access opportunities.

At Celero, we prioritize rigorous adherence to established Standard Operating Procedures (SOPs) to guarantee top-tier quality in our clinical trials. Our dedicated teams are continually trained on both trial protocols and Good Clinical Practice (GCP), ensuring a consistent level of expertise across the board.


We emphasize regular site monitoring to validate data accuracy and uphold patient safety, supplemented by periodic independent audits that ensure consistent compliance and protocol adherence. Our adoption of validated electronic data capture systems is a testament to our commitment to unparalleled data integrity.


Our proactive risk management strategies, coupled with our transparent communication lines with stakeholders, mean that potential challenges are addressed promptly and efficiently. By placing unwavering emphasis on participant safety, maintaining meticulous records, strictly adhering to regulatory guidelines, and integrating constructive feedback mechanisms, we strive to consistently raise the bar for the quality and integrity of clinical trials.

Our startup & recruitment timelines are significantly shorter due to:  

  • Relationship and Experience with Regulators: We understand their expectations for submission contents. 
  • Strategic Country Selection: We opt for countries with commercial opportunities and unmet needs. This not only provides accelerated startup phases but also faster recruitment due to large populations in emerging markets and high prevalence of specific diseases,  in addition to accelerated registration in some cases. 
  • Recruitment Efficiency: Our access to large populations in emerging markets, combined with our global reach for multi-centric trials and collaboration with experienced Principal Investigators (PIs) in specific disease areas, expedites our recruitment process. 

Additionally, we have access to patient databases through our sites and PIs, ensuring a smoother recruitment phase. 

A cost-controlled agreement is our promise to efficiently manage the costs associated with your clinical trial, keeping them within the agreed budget. This offers a fixed clinical trial budget that is both predictable and controlled. This allows you to trust our services, knowing that unexpected costs and change orders are unlikely. At Celero we demonstrate financial responsibility, fostering a transparent and trusting relationship with our sponsors. 

We understand that every biotech company has unique needs. Our approach is tailored to your requirements, ensuring that every phase of the clinical trial, from startup to recruitment and final reporting, aligns with your specific objectives, outcomes, budget, and timelines. 

We do not only perform a scientific experiment (Clinical trial); At Celero we strategically select countries with high commercial and growth opportunities by addressing their unmet  needs. These strategies allow our sponsors to achieve accelerated registrations and high market share providing you with an optimal return on your clinical trial investment. 

Our partnership model signifies a collaborative approach. We don't see ourselves as just another vendor; we act as an extension of your clinical, registration and commercial team. This symbiotic relationship ensures that your objectives become our milestones, driving both parties towards shared success. 

Celero enabler, global industry experts

Global Industry Experts

Celero enabler, key opinion leaders, regulators and sites

Key Opinion Leaders, Regulators and Sites

Celero enabler, naive diverse high prevalence patients

Naive, Diverse and High Prevalence Patiences

Your Global Industry Experts

Our global experts have unique expertise in the development and registration of vaccines and biologic drugs.

Celero Executive team have experience in 80 trials across multiple clinical development phases (P1-P4) in more than 25 countries (APAC, LATAM, MEA, Eurasia, EU, Central & Eastern Europe).

Celero global industry experts

Therapeutic Areas of Expertise

At Celero, we prioritize rigorous adherence to established Standard Operating Procedures (SOPs) to guarantee top-tier quality in our clinical trials. Our dedicated teams are continually trained on both trial protocols and Good Clinical Practice (GCP), ensuring a consistent level of expertise across the board.


We emphasize regular site monitoring to validate data accuracy and uphold patient safety, supplemented by periodic independent audits that ensure consistent compliance and protocol adherence. Our adoption of validated electronic data capture systems is a testament to our commitment to unparalleled data integrity.


Our proactive risk management strategies, coupled with our transparent communication lines with stakeholders, mean that potential challenges are addressed promptly and efficiently. By placing unwavering emphasis on participant safety, maintaining meticulous records, strictly adhering to regulatory guidelines, and integrating constructive feedback mechanisms, we strive to consistently raise the bar for the quality and integrity of clinical trials.

Our startup & recruitment timelines are significantly shorter due to:  

  • Relationship and Experience with Regulators: We understand their expectations for submission contents. 
  • Strategic Country Selection: We opt for countries with commercial opportunities and unmet needs. This not only provides accelerated startup phases but also faster recruitment due to large populations in emerging markets and high prevalence of specific diseases,  in addition to accelerated registration in some cases. 
  • Recruitment Efficiency: Our access to large populations in emerging markets, combined with our global reach for multi-centric trials and collaboration with experienced Principal Investigators (PIs) in specific disease areas, expedites our recruitment process. 

Additionally, we have access to patient databases through our sites and PIs, ensuring a smoother recruitment phase. 

A cost-controlled agreement is our promise to efficiently manage the costs associated with your clinical trial, keeping them within the agreed budget. This offers a fixed clinical trial budget that is both predictable and controlled. This allows you to trust our services, knowing that unexpected costs and change orders are unlikely. At Celero we demonstrate financial responsibility, fostering a transparent and trusting relationship with our sponsors. 

We understand that every biotech company has unique needs. Our approach is tailored to your requirements, ensuring that every phase of the clinical trial, from startup to recruitment and final reporting, aligns with your specific objectives, outcomes, budget, and timelines. 

We do not only perform a scientific experiment (Clinical trial); At Celero we strategically select countries with high commercial and growth opportunities by addressing their unmet  needs. These strategies allow our sponsors to achieve accelerated registrations and high market share providing you with an optimal return on your clinical trial investment. 

Our partnership model signifies a collaborative approach. We don't see ourselves as just another vendor; we act as an extension of your clinical, registration and commercial team. This symbiotic relationship ensures that your objectives become our milestones, driving both parties towards shared success. 

Navigating the complex world of medical innovation requires a partner with deep-rooted expertise across a diverse range of therapeutic areas. Our clinical trial services extend beyond traditional boundaries to meet the unique demands of each domain.

Celero Infectious Diseases CRA thumbnail

Immunology & Infectious Disease CRO

In an ever-evolving global health landscape, immunology & infectious diseases remain at the forefront of medical research and challenges.

Our commitment runs deep in pioneering clinical research for genetic and rare diseases.

Celero Rare and Genetic Disease CRO thumbnail
Celero Oncology CRO thumbnail

Oncology CRO

At Celero, we seamlessly blend technological advancements with hands-on expertise, setting the benchmark for excellence in cancer research.

Medical Device CRO

Conducting a clinical study is crucial for medical device manufacturers, necessitating a strategic approach. Celero navigates sponsors from clinical strategy formulation to final reporting.

Learn more about our Medical Device CRO offering >

Celero Medical Device CRO thumbnail

Quality Compliance

Our commitment to quality, integrity, and reliability is reflected in our comprehensive compliance with international standards and regulatory requirements.

Our Quality Management System (QMS) is fully aligned with ISO 9001 standard, FDA and EMA requirements, ensuring that our methodologies and practices adhere to the rigorous standards expected in our industry.


In addition, our QMS is built in a direction that will ensure the integration of the following standards


  • ISO 14001
  • ISO 27001
  • ISO 45001
  • ISO 22301
  • ISO 37001

Your Key Opinion Leaders, Regulators and Sites

As a leading Contract Research Organization (CRO), we have fostered lasting relationships with pivotal players in the field of clinical research.

At Celero, we prioritize rigorous adherence to established Standard Operating Procedures (SOPs) to guarantee top-tier quality in our clinical trials. Our dedicated teams are continually trained on both trial protocols and Good Clinical Practice (GCP), ensuring a consistent level of expertise across the board.


We emphasize regular site monitoring to validate data accuracy and uphold patient safety, supplemented by periodic independent audits that ensure consistent compliance and protocol adherence. Our adoption of validated electronic data capture systems is a testament to our commitment to unparalleled data integrity.


Our proactive risk management strategies, coupled with our transparent communication lines with stakeholders, mean that potential challenges are addressed promptly and efficiently. By placing unwavering emphasis on participant safety, maintaining meticulous records, strictly adhering to regulatory guidelines, and integrating constructive feedback mechanisms, we strive to consistently raise the bar for the quality and integrity of clinical trials.

Our startup & recruitment timelines are significantly shorter due to:  

  • Relationship and Experience with Regulators: We understand their expectations for submission contents. 
  • Strategic Country Selection: We opt for countries with commercial opportunities and unmet needs. This not only provides accelerated startup phases but also faster recruitment due to large populations in emerging markets and high prevalence of specific diseases,  in addition to accelerated registration in some cases. 
  • Recruitment Efficiency: Our access to large populations in emerging markets, combined with our global reach for multi-centric trials and collaboration with experienced Principal Investigators (PIs) in specific disease areas, expedites our recruitment process. 

Additionally, we have access to patient databases through our sites and PIs, ensuring a smoother recruitment phase. 

A cost-controlled agreement is our promise to efficiently manage the costs associated with your clinical trial, keeping them within the agreed budget. This offers a fixed clinical trial budget that is both predictable and controlled. This allows you to trust our services, knowing that unexpected costs and change orders are unlikely. At Celero we demonstrate financial responsibility, fostering a transparent and trusting relationship with our sponsors. 

We understand that every biotech company has unique needs. Our approach is tailored to your requirements, ensuring that every phase of the clinical trial, from startup to recruitment and final reporting, aligns with your specific objectives, outcomes, budget, and timelines. 

We do not only perform a scientific experiment (Clinical trial); At Celero we strategically select countries with high commercial and growth opportunities by addressing their unmet  needs. These strategies allow our sponsors to achieve accelerated registrations and high market share providing you with an optimal return on your clinical trial investment. 

Our partnership model signifies a collaborative approach. We don't see ourselves as just another vendor; we act as an extension of your clinical, registration and commercial team. This symbiotic relationship ensures that your objectives become our milestones, driving both parties towards shared success. 

Clinical Trial Sites. Our partnerships with diverse clinical trial sites ensure seamless alignment and facilitate innovative trials, reflecting our commitment to quality and ethics.

Key Opinion Leaders (KOLs) We actively engage with renowned industry experts and thought leaders, integrating their insights to keep our research strategies at the forefront of scientific excellence.

Regulatory Bodies. Open dialogues with regulatory authorities across various jurisdictions underscore our dedication to responsible research. We navigate the regulatory landscape with finesse, ensuring that our clients' projects align with all international standards and local regulations.

Your Access to Diverse and Specialised Patient Populations

Our strategic partnerships enable unparalleled access to distinct patient groups, enhancing our clinical trials' scope and significance.

At Celero, we prioritize rigorous adherence to established Standard Operating Procedures (SOPs) to guarantee top-tier quality in our clinical trials. Our dedicated teams are continually trained on both trial protocols and Good Clinical Practice (GCP), ensuring a consistent level of expertise across the board.


We emphasize regular site monitoring to validate data accuracy and uphold patient safety, supplemented by periodic independent audits that ensure consistent compliance and protocol adherence. Our adoption of validated electronic data capture systems is a testament to our commitment to unparalleled data integrity.


Our proactive risk management strategies, coupled with our transparent communication lines with stakeholders, mean that potential challenges are addressed promptly and efficiently. By placing unwavering emphasis on participant safety, maintaining meticulous records, strictly adhering to regulatory guidelines, and integrating constructive feedback mechanisms, we strive to consistently raise the bar for the quality and integrity of clinical trials.

Our startup & recruitment timelines are significantly shorter due to:  

  • Relationship and Experience with Regulators: We understand their expectations for submission contents. 
  • Strategic Country Selection: We opt for countries with commercial opportunities and unmet needs. This not only provides accelerated startup phases but also faster recruitment due to large populations in emerging markets and high prevalence of specific diseases,  in addition to accelerated registration in some cases. 
  • Recruitment Efficiency: Our access to large populations in emerging markets, combined with our global reach for multi-centric trials and collaboration with experienced Principal Investigators (PIs) in specific disease areas, expedites our recruitment process. 

Additionally, we have access to patient databases through our sites and PIs, ensuring a smoother recruitment phase. 

A cost-controlled agreement is our promise to efficiently manage the costs associated with your clinical trial, keeping them within the agreed budget. This offers a fixed clinical trial budget that is both predictable and controlled. This allows you to trust our services, knowing that unexpected costs and change orders are unlikely. At Celero we demonstrate financial responsibility, fostering a transparent and trusting relationship with our sponsors. 

We understand that every biotech company has unique needs. Our approach is tailored to your requirements, ensuring that every phase of the clinical trial, from startup to recruitment and final reporting, aligns with your specific objectives, outcomes, budget, and timelines. 

We do not only perform a scientific experiment (Clinical trial); At Celero we strategically select countries with high commercial and growth opportunities by addressing their unmet  needs. These strategies allow our sponsors to achieve accelerated registrations and high market share providing you with an optimal return on your clinical trial investment. 

Our partnership model signifies a collaborative approach. We don't see ourselves as just another vendor; we act as an extension of your clinical, registration and commercial team. This symbiotic relationship ensures that your objectives become our milestones, driving both parties towards shared success. 

Treatment-Naive Patients. We offer connections to treatment-naïve patients, providing a controlled perspective for evaluating new therapeutic interventions.

High Disease Prevalence Patients. Our networks reach populations where specific diseases are prevalent, facilitating focused study and vital insights into potential treatment pathways.

Clinically Diverse Population. Our access to demographically and clinically diverse populations ensures representative and comprehensive research, reflecting real-world complexities.

Celero's ability to tap into these unique patient groups reflects our commitment to innovative and nuanced research. By embracing this clinical trial diversity, we are driving innovation in healthcare, unlocking new possibilities, and aligning with real-world medical challenges.

Our Vision
Healing humanity one Biotech at a time

Clinical Trail Expert

Speak to an Expert

Speak to an Expert

Share by: